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Zika virus is a new global threat for 2016 that has been swept to almost all Americas and
is now posing serious threats to the entire globe. This deadly virus is playing havoc to
unborn lives because of its reported association with upsurge of fetal deformation called
microcephaly and neuropathic disorders including Guillain-Barre´ syndrome. Till today,
there is no vaccine prospect, antiviral therapy or licensed medical countermeasures to
curb the teratogenic outcomes of this destructive viral infection. Diagnosis, treatment,
chronicity and pathogenesis are still vague and unsettled. Therefore, this review article
addresses all the aspects related to this disease to mitigate the explosive rise in Zika virus
infection.1. Introduction and epidemiology
Zika virus (ZIKV) is a mosquito-borne RNA virus infection
related to yellow fever, dengue and West Nile virus. Zika virus
is generally transmitted by bite of an infected Aedes species of
mosquito. Zika virus poses serious threats to pregnant women
[1]. An increased risk of Guillain-Barre´ syndrome and several
other congenital neurological abnormalities associated with
Zika virus have also been reported [2]. Zika virus infection is
clinically similar to dengue fever and cause acute febrile
illness, arthralgia, fever, myalgia, rash, headache and
conjunctivitis [3,4]. The diagnosis of Zika virus infection is
veriﬁed by detection of viral genome using RT-PCR genomic
ampliﬁcation and viral isolation [5].
According to phylogenetic studies, Zika virus emerged in
East Africa during early 20th century and later on spread to
Southeast Asia. The virus was named after the forest in Uganda
from where it was ﬁrst isolated in rhesus monkey in 1947 [5] and
identiﬁed in 1952 in human beings. Another study conﬁrmed
seven patients with serologic evidence of Zika virus infection
in Indonesia [6]. In 2007 a small-scale outbreak was docu-
mented in Yap, Federated States of Micronesia [7] followed by alarger outbreak in French Polynesia during 2013 with 28 000
cases reported in the ﬁrst 4 months [8–10]. Since May 2015,
Zika virus infection has been escalated to 1.5 million cases in
Northeastern Brazil and now the virus has been transmitted to
South and Central America and Caribbean [10–12].
Approximately 440000–1300000 cases of Zika virus in Brazil
alone were reported during an outbreak of 2015 [2]. Pan
American Health Organization conﬁrmed copious cases of
Zika virus infection in French Guiana, Venezuela, Paraguay,
Guatemala, Mexico, Honduras, El Salvador, Colombia,
Panama and Suriname. Besides America, Atlantic island of
Cape Verde reported its ﬁrst Zika outbreak in October 2015
with 4744 suspected cases by 6 December 2015 [13].
Currently, more than 4500 microcephaly cases have been
identiﬁed [14]. In December 2015, Netherlands conﬁrmed the ﬁrst
domestic case of microcephaly (abnormal small size of head) in a
neonate whose mother was back from Surinam followed by 20
more cases all imported from Surinam [15]. The average
number of live births in Brazil is around 1242975 (2009–2013
data) but a considerable increase in microcephaly was reported
in Pernambuco state, Northeast Brazil. Since beginning of
2016, 46 deaths in 20 states and the Federal District has been
surveyed and this rate is signiﬁcantly higher than 2010–2014,
during which an average of 163 (standard deviation 16.9)
cases of microcephaly were reported nationwide (26 states and
1 Federal District) per year [16].
A research based study applied complement-ﬁxation test re-
actions to 372 samples of serum (43 from humans, 172 fromunder the CC BY-NC-ND license (http://
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containing eight viruses belonging to family Togavirida fol-
lowed by identiﬁcation of antibodies targeted towards each
tested virus. The most elevated over-all prevalence rates were:
7.8% West Nile virus, Japanese 3.2% encephalitis virus and
2.4% Zika virus, followed by 1.6%–1.3% Sindbis virus, Chi-
kungunya virus, Uganda virus and Royal Farm viruses [7,17].
2. Virus structure and genome organization
Zika virus is positive-sense single-stranded RNA virus which
belongs to the family Flaviviridae consisting of 11000 bases
approximately. The genome consists of 50 and 30 untranslated
regions ﬂanking a single open reading frame which encodes only
one polyprotein that cleaves into three structural proteins, capsid
protein, premembrane/membrane protein, envelope protein,
along with seven non-structural proteins (NS1, NS2A, NS2B,
NS3, NS4A, 2K, NS4B, and NS5) [18].
A previously done genetic study based on nucleotide se-
quences derived from the NS5 gene unfolded three Zika virus
lineages: East African, West African and Asian [19,20].
Till today, scientists were familiar with little knowledge
regarding the genetic relationships between strains of Zika virus
collected from Africa and Asia. Furthermore, the geographical
origins of the strains behind human related Zika virus outbreak
on Yap Island in Federated States of Micronesia, and that of
Cambodia were undetermined. But genomic comparison
revealed several sub-clades exhibiting two major geographically
distinct lineages of Zika virus i.e., Asian and African. During the
past 50 years, the virus has spread in entire Southeast Asia later
on, it invaded Yap Island causing human epidemic in 2007, and
proved the etiology of a pediatric case of ZIKV infection in
Cambodia during 2010 [20].
3. Potential transmission of Zika virus
Zika virus has the potential to attack any area where the
Aedes mosquito vector is present [5,21]. Zika virus has been
isolated from Aedes furcifer, Aedes africanus, Aedes
apicoargenteus, Aedes luteocephalus, Aedes vittatus, and
Aedes aegypti (Ae. aegypti) mosquitoes [22–25]. It has been
reported that Aedes hensilii was the most frequently found
mosquito species present on Yap island during the Zika virus
epidemic of 2007 [7]. Zika virus infection was transmitted by
Ae. aegypti during the recent outbreak of Brazil [2].
Epidemiological studies in Uganda had suggested that Aedes
africanus was a vector of Zika virus [26,27].
Studies indicate that the usual mosquito vectors in Asia are
Ae. aegypti and Aedes albopictus (Ae. albopictus) [20].
Ae. albopictus is considered as invasive mosquito because of
its transportation to other continents through commerce [28]. In
Brazil, Ae. albopictus was present in 59% of municipalities in
2014 [29] and spread to 24 of 27 states [30]. This vector is able
to adapt to both urban and sylvatic habitats, including
bromeliads [31] perforated bamboo internodes [32], and tree
holes (also with Ae. aegypti and Aedes vittatus) [33], and is a
suspected link for yellow fever virus between preserved and
modiﬁed environments in the south and southeast regions of
Brazil [34]. Ae. albopictus species feed on wide range of hosts
because it is endophagic and exophagic, as compared to
Ae. aegypti that usually feeds on humans.Transmission of Zika virus by blood transfusion has been
conﬁrmed during the recent outbreak of Zika virus that invaded
7 Brazilian States [35].
In 2013, French Polynesia faced the largest reported outbreak
of Zika virus infection. To escape the Zika virus transmission by
blood transfusion, speciﬁc nucleic acid testing of blood donors
was performed which indicated that 3% (42 out of 1505) blood
donors were positive for Zika virus by PCR from November,
2013 to February, 2014. Therefore, blood safety authorities were
recommended to get alert in order curb the risk of Zika virus
infection through blood transfusion [36]. During a Zika virus
outbreak in French Polynesia, Zika virus was identiﬁed and
isolated from the semen of a patient in Tahiti when he
underwent treatment for hematospermia. This observation
supports the fact that Zika virus can also be transmitted by
sexual intercourse [4]. In 2008, another evidence of Zika virus
infection by sexual intercourse had also been reported in a
patient in southeastern Senegal [37]. Zika virus can attack
pregnant ladies in all three trimesters [38]. Vertical, maternal
fetal transmission or perinatal transmission of Zika virus has
also been reported. The possible routes of transmission were
breastfeeding, close contact between mother and newborn and
transplacental during delivery [9] (Figure 1).
4. Pathogenesis of ZIKV
Very little information is known about the pathogenesis of
Zika virus but ﬂaviviruses transmitted by mosquitos replicate in
dendritic cells near the site of inoculation and later on lead to
blood stream and lymph nodes [39]. It is generally considered that
ﬂaviviral replication occurs in cellular cytoplasm but another
study demonstrated that Zika virus antigens might be found in
infected cell nuclei [40]. Till today, infectious Zika virus has
identiﬁed in blood of humans as early as the day of onset of
disease but nucleic acid of virus was conﬁrmed as late as 11 d
after onset of illness [41]. Human skin is an important portal for
the entry of Zika virus and act as major contributor in the
induction of antiviral immune responses. It has been reported
that immature dendritic cells, epidermal keratinocytes and
dermal ﬁbroblasts were responsible for Zika virus outbreak
occurred in French Polynesia. There are number of adhesion
factors like DC-SIGN (known as CD209), Tyro3, AXL and, to
a lesser extent, TIM-1 which support Zika virus entry, with a
dominant role attributed to TAM receptor AXL. The use of
neutralizing antibody and speciﬁc RNA silencing conﬁrmed Zika
virus permissiveness of human skin ﬁbroblasts. Zika virus trig-
gered the transcription of Toll-like receptor 3, retinoic acid-
inducible gene 1, Melanoma Differentiation-Associated protein
and various interferon stimulated genes like MX1, OAS2, and
ISG15 characterized by strongly boosted gene expression of beta
interferon. Zika virus was sensitive to the antiviral reactions of
both type I and type II interferons. The infection of skin ﬁbro-
blasts lead to production of autophagosomes that were linked
with increased replication of virus inﬂuenced by a chemical
inducer of autophagy i.e., Torin 1, and the speciﬁc autophagy
inhibitor 3-methyladenine [42].
5. Clinical manifestation of ZIKV
It has been documented that majority (about 73%) of Zika
virus infections are asymptomatic [7]. In case of symptomatic
Figure 1. History of Zika virus transmission.
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and is difﬁcult to distinguish from dengue and chikungunya
infections. Formation of maculopapular skin rash on the face
or trunk that may get more diffused, headaches, low-grade fe-
ver, conjunctivitis myalgia and arthralgias are most common
symptoms of Zika virus infection [37,43–45]. A study
demonstrated that commonly reported symptoms during the
most recent outbreak of Puerto Rico that occurred from
November 23, 2015 to January 28, 2016, included 77% rash,
77% myalgia, 73% arthralgia and fever 73% [46]. Seven
Indonesian patients who were Zika virus positive experienced
high fever, diarrhea, stomach aches, malaise, vomiting,
dizziness, chills, anorexia, leg pain, lymphadenopathy and
hypotension [6]. In many cases abnormal development of small
size head or microcephaly has been observed, with
hydrocephalus, agyria and multifocal dystrophic calciﬁcations
in the subcortical white matter and cortex, along with mild
focal inﬂammation and cortical displacement [47]. According
to a research based study, Zika virus epidemics in the
Americas and Brazil has unveiled the deleterious effects of
virus on fetuses like development of hydrops fetalis, an
atypical condition associated with an abnormal accumulation
of ﬂuid in the fetus, as well as serious central nervous system
defects like hydranencephaly and microcephaly. After the
death of fetus, Zika virus RNA was identiﬁed in amniotic
ﬂuid and tissues of central nervous system. Additionally, this
case study provides weighty evidence that besides
microcephaly, there may be an association between Zika virus
disease and hydrops fetalis alongside fetal demise in some
cases [14,48].
Apart from microcephaly, other possible outcomes in neo-
nates positive for Zika virus include ventricular enlargement,
brain atrophy, and intracranial calciﬁcations [49]. Several casesof suspected congenital Zika virus infection have been
associated with scalp rugae, ocular defects and joint
contractures [9,49–51]. Besides, brain abnormalities in
newborns, Zika virus RNA has been conﬁrmed in the
pathologic tissue specimens of fetal deaths, however, there is
no sound evidence which proves that Zika virus causes the
fetal demise [52]. Several studies have linked Zika virus with
Guillain-Barre syndrome and in early 2014 the ﬁrst recorded
case of Zika virus infection complicated by Guillain-Barre
syndrome was identiﬁed in French Polynesia [3]. Since then,
French Polynesian health surveyors started making efforts to
report Guillain-Barre syndrome cases that were considered to
be secondary to the primary Zika virus infection [45].
6. Zika virus diagnostics
The detection of Zika virus infection is based on the identi-
ﬁcation of viral RNA in blood samples. RT-PCR along with
conﬁrmation and isolation of virus in the blood samples
collected during the early ﬁve days of emergence of infection are
the reference techniques. The ‘pan ﬂavivirus’ ampliﬁcation
technique together with sequencing may also be used as an
alternative or a substitute [18,53]. The viremic period of humans
could be brief, from the third to the ﬁfth day after the onset of
Zika virus infection symptoms. Viruria could stay for a longer
time than viremia and the real time RT-PCR detection of viral
RNA in urine could be a substitute if genetic material in the
serum is no longer present [21,54]. In 2014, a case study
demonstrated that Zika virus RNA was conﬁrmed by RT-PCR
in the urine of Japanese traveller returned from Thailand
whereas serological tests showed cross reactivity of IgM against
the dengue virus indicating that Zika could be misdiagnosed [55].
Pregnant women infected with Zika virus or exposed to it, must
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examination. This includes asymptomatic patients having
symptoms outside the testing window and those who are Zika
virus negative by RT-PCR. Microcephaly is an abnormal con-
dition with head circumference less than the 2.5th centile for
gestational age and USS has been proved a sensitive screening
test for microcephaly apace with other intracranial abnormalities
like ventriculomegaly and calciﬁcation. Fetal brain MRI has the
ability to detect abnormalities not observed on USS. Micro-
cephaly association with Zika virus is just a tip of an iceberg
because microcephaly and other intracranial abnormalities may
also be caused by a number of disorders unrelated to Zika virus
[56]. A case study demonstrated that RT-PCR assay conﬁrmed
Zika virus in the brain tissues of fetus that was compatible with
observations of electron microscope and the whole genome of
Zika virus was recovered from the fetal brain. Calciﬁcations in
the placenta and fetal brain were noticed when ultrasonography
was performed at 29 weeks of gestation [47].
Generally, for the diagnosis of ﬂavivirus infections acute-
phase serum sample must be collected soon after the onset of
ailment followed by collection of second sample 2–3 weeks after
the ﬁrst. Therefore, Zika virus is usually diagnosed by PCR test
done on acute phase serum samples that detect viral RNA
whereas, other tests facilitate the detection of speciﬁc antibody
against Zika virus in serum. Arboviral Diagnostic and Reference
Laboratory of the Centers for disease Control and Prevention
(Atlanta, GA, USA) has developed ELISA for detection of
immunoglobulin IgM against Zika virus. Samples collected from
Yap Island, Federated States of Micronesia exhibited that cross-
reactivity in sera from convalescent phase patients occurred
more commonly among patients who had previously been
exposed to ﬂavivirus infections than among those who were
suffering from primary Zika virus infections.
A study elucidated that IgM was detectable during the early
three days of onset of infection in some patients but one person
previously exposed to ﬂavivirus infection had not developed
IgM even at ﬁfth day but had it by eighth day. Neutralizing
antibody was developed during the early ﬁve days of onset of
disease. Immunoassays have ameliorated speciﬁcity than plaque
reduction neutralization assay; however, the possibility of cross-
reactivity in secondary ﬂavivirus infections is always there.
Polymerase Chain Reaction tests can be performed on samples
collected even at the ﬁrst day of onset of illness but viral RNA
may also be conﬁrmed as late as 11 d after the onset of disease
[7,19,21]. A female patient returned from Thailand visited a local
emergency department with mild symptoms like fever and
papular rash and underwent a test for malaria, measles and
dengue. When the conserved region of the non-structural pro-
tein 5 gene of the genus Flavivirus was ampliﬁed, the yielded
PCR product exhibited 99% sequence match with Zika virus.
Nasopharyngeal swab and urine sample collected for measles
research were also positive for Zika virus by RT-PCR. There-
upon, Zika virus was isolated in cell culture, using urine sample.
This case study revealed several novel laboratory and clinical
ﬁndings along with the ﬁrst and second documentation of ZIKV
in Canada and Thailand, respectively [57].
7. Zika virus association with Guillain-Barre´
syndrome and microcephaly
The current epidemic of microcephaly supported the hy-
pothesis that ZIKV was the most possible cause of thiscongenital syndrome. A striking increase in the micocephaly
cases in newborns has been reported in Brazil in November 2015
[11]. Till day, >4500 microcephaly cases have been conﬁrmed
(Brazil Ministry of Health, 2016). There are number of
microcephaly cases identiﬁed in 9 Brazilian states so far. By
28 November 2015, 646 cases of microcephaly had been
diagnosed in Pernambuco state alone [49].
Death of newborns have been reported because of patho-
logical lesions or ultrasound abnormalities which were limited to
the central nervous system [48,49]. Another case study reported in
the February 2016 presented symptoms of hydranencephaly that
developed hydrops fetalis and death of fetus because of
congenital Zika virus infection [14]. In 2015, about 4000
suspected cases of microcephaly has been reported in Brazil,
depicting a 20-increase in prevalence (from 2010 to 2014) [58].
Virus has been detected in the brains of neonates and in the
placenta and amniotic ﬂuid of mothers but according to some
studies causative link between microcephaly and Zika virus is
yet to be established. Whereas, on January 15, 2016, Hawaii
documented the ﬁrst case of microcephaly in a neonate whose
mother was just back from Brazil. During next few days,
several other cases of microcephaly were reported in Florida,
Illinois and Texas after international travel [59]. From October,
2013 to April, 2014, French Polynesia faced the largest Zika
virus outbreak and an increased number of cases of Guillain-
Barre´ syndrome were reported during the same period, thus
supporting a possible link of Guillain-Barre´ syndrome with
Zika virus. About 42 out of 32000 Zika virus positive patients
were diagnosed with Guillain-Barre´ syndrome at the Centre
Hospitalier de Polyne´sie Française in Tahiti. The study also
revealed that about 88% of the patients with Guillain-Barre´
syndrome were positive for Zika virus [5,60]. Twenty fold
increase in incidence of Guillain-Barre´ syndrome has been
reported [61]. A very recent study has provided sound evidence
that proved Zika virus infection as cause of Guillain-Barre´
syndrome [62,63] (Figure 2).
8. Prevention and treatment
Pregnant women should stay out of travelling to areas which
are exposed to Zika virus outbreaks and must visit travel health
specialist and incase, travelling is unavoidable because of any
circumstances they must consult travel health specialist and
should regularly apply mosquito repellants [56]. Zika virus has
the ability to invade newer areas where the Aedes mosquito
vector is present and may become the risk for entire globe
therefore, Zika virus control practice like mosquito vector
eradication is necessary and must follow standard mosquito
protection advice [5]. United Kingdom has advised a guideline
that any pregnant woman back from Zika-affected country
must pay a visit to obstetrician or general physician. Travellers
must avoid getting pregnant in an affected area and for 28 d after
returning to United Kingdom males are recommended to use
condoms [64]. Pregnant women positive for Zika virus RT-PCR
need to consider serial fetal ultrasounds every 3–4 weeks [52]
and must visit a fetal medicine service for follow up including
amniocentesis from 15 weeks to identify Zika virus alongside
other neonatal infection in the amniotic ﬂuid [56]. To treat the
symptoms of Zika virus, Centre for Disease Prevention and
Control has issued some guidelines like taking plenty of rest,
increased ﬂuid intake to prevent dehydration, fever and pain
relief medicines, avoid taking aspirin and non-steroidal anti-
Figure 2. Graph representing suspected cases of Zika virus infections and Guillain-Barre Syndrome [63].
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must wear long-sleeved shirts and pants and must ensure the
use of doors and windows with intact screens alongside EPA
(environmental protection agencies) registered insect repellants
and permethrin-treated clothing [46]. The transmission of ZIKV
through blood transfusion was reported in epidemic that hit
French Polynesia and the inactivation of pathogen present in
blood is the most powerful strategy to mitigate transfusion-
transmitted ZIKV infection. A study demonstrated the efﬁ-
ciency of ZIKV inactivation by ultraviolet A illumination and
amotosalen. Both amotosalen and ultraviolet a light combined
thus, lead to an inactivation of Zika virus in fresh-frozen plasma.
This process of inactivation control plasma transfusion-
transmitted Zika virus infections [66]. There is no antiviral
therapy developed yet and care is a supportive therapy to
resolve symptoms [58]. Effective and safe Zika virus vaccine
will probably be developed in next 3–10 years even with
speedy research. In late 2015, the National Institutes of Health
started an initiative for development of Zika virus, and Brazil
has accelerated vaccine development. Insecticide spraying of
mosquito habitats is an effective strategy to avoid Zika [59].
Eliminate water reservoirs and containers because stagnant
water acts as breeding site for Aedes mosquito that is a vector
for Zika virus [67]. Hydroxychloroquine which is an anti-
malarial drug acts as inhibitor of autophagy. In vitro testing
elucidated the control of dengue virus infection through accu-
mulation and induction of reactive oxygen species along with
mitochondrial antiviral signaling protein. Amodiaquine another
autophagy inhibitor and hydroxychloroquine have been proved
safe even in pregnancy. Amodiaquine acts as inhibitor of Ebola
virus. It has been reported that in preliminary cell culture studies,
amodiaquine has been conﬁrmed as an agent that curbs the Zika
virus pathogenicity at similar concentrations to those already
recorded for Ebola virus (unpublished results of Drs. V Soloveva
and S Bavari) [68].
9. Future prospects
Medical countermeasure strategies like neutralizing antibody
preparations, development and testing of antiviral drugs along
with medicines aiming to impede Fc receptor interactions mustbe evaluated during the ﬁrst and second trimesters of pregnancy
because pregnant women are at a greater risk of acquiring Zika
virus infection [69–71]. Institute Butantan which is Brazilian
biomedical research center, is working on anticipated Zika
vaccine projected for accomplishment in next three to ﬁve
years. Previous researches and experience suggests that this is
the most rational approach and optimistic plan for vaccine
development and licensure, which may take more than 20
years of clinical development alongside testing [68,72].
Production of prophylactic vaccine targeting Zika virus-
induced disease will need signiﬁcant time and heedful safety
evaluation and efﬁcacy for the population. This is true for vac-
cine designed to target virus responsible for teratogenic effects
and autoimmune disease (GB Syndrome) of neurologic disor-
ders caused due to Zika virus infection [73,74].
There is no vaccine currently available, therefore develop-
ment of therapeutics and prophylactics must be probed and
studied thoroughly. Development of targeted immunothera-
peutic strategies may inhibit Zika infection including GB Syn-
drome, and ADE (Antibody Dependent Enhancement) that has
been demonstrated with Zika virus. Monoclonal antibody based
therapies for arbovirus infections is a promising approach that
must be evaluated carefully given the potential challenge of
Antibody Dependent Enhancement. Therapeutic and prophy-
lactic use of cross-reactive neutralizing monoclonal antibodies
for ﬂavivirus infections has been observed potent and efﬁcacious
in animal models. The production of De novo antibodies is
possible, and these antibodies attack Zika-speciﬁc epitopes.
Appropriately engineered and de-risked monoclonal antibodies
possess the ability to mitigate Zika virus infection, but mono-
clonal antibody product should be highly potent if it is to yield
sufﬁcient number of doses at reasonable cost.
10. Conclusions
Because of current explosive rise in Zika virus, there is a dire
need to carry out research based study to comprehend this life-
threatening disease and develop medical countermeasures. Zika
virus is a complex challenge than Ebola as it may infect more
lives especially unborn fetus and is invading the entire globe
very rapidly. Currently, there is not enough epidemiological and
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Garnering this information must be the priority. Gaining ground
is the most rational approach that it would be a relatively
affordable insurance policy to develop experimental treatments
especially vaccines, against an array of potential threats. The
short-term actions must be to combat the vector directing to
reduce the vector density and long-term action is the develop-
ment of anti-viral therapy or vaccine to alleviate the blooming
risk of Zika virus.
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